focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 22.50
Bid: 22.00
Ask: 24.00
Change: 0.00 (0.00%)
Spread: 2.00 (9.091%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 22.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Win

27 Nov 2009 07:00

RNS Number : 1665D
Angle PLC
27 November 2009
 



For immediate release

27 November 2009

ANGLE plc ("the Company")

Contract Win

ANGLE plc ("ANGLE"), the international venture management company focusing on the commercialisation of technology and innovation, is delighted to announce a new contract win for its Management Services business worth £2.3 million over three years.

The contract, which was the subject of a competitive tendering process, is to deliver Innovation Advice and Guidance in Lincolnshire, a product in the UK Government's Solutions for Business portfolio, on behalf of Lincolnshire County Council. The contract follows ANGLE's successful delivery oa previous programme, Innovation Lincolnshire, since May 2007. 

 

The programme brings the techniques and benefits of innovation to small businesses, identifying openings for innovation based business improvement. These include stimulating growth through the introduction of new products and services and delivering operational improvement through innovative business process change.  ANGLE's specialist consultants provide complete SME innovation support service, from innovation opportunity identification, training, business analysis and support to project implementation.

Innovation is considered by Lincolnshire's public sector partners to be crucial to the county's development and prosperityDeveloped as part of the Lincolnshire Economic Strategy, the Programme is part of the county's  contribution to the East Midlands Regional Innovation Strategy.

Commenting on the award of this new contract, Programme Director Dr Shane Booth said: 

"We are delighted to have been given the opportunity to continue working with delivery partners and businesses across Lincolnshire. Our success in securing this contract reflects the methodologies, delivery processes, expertise and management we have developed to drive innovation. In the earlier programme, we deployed these to assist projects as diverse as the development of new musical instruments, designing special packaging to redeploy a bulk product for retail sale and the creation of a new, mobile biomass heating system."

ANGLE Founder and Chief Executive, Andrew Newland, added:

"This contract confirms the attraction of our capabilities and approach to public sector organisations seeking to deploy technology and innovation as tools for business growth and consequent regional economic development. Our strategy of focusing on long term contracts in cases where we can add substantial value continues to be highly successful for ANGLE. We look forward to the potential of rolling out these capabilities throughout the UK and beyond."

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

Collins Stewart Europe Limited

Stewart Wallace

0207 523 8350

Scott Harris 

Stephen Scott, James O'Shaughnessy, Harry Dee

0207 653 0030

Notes to Editors

ANGLE plc 

Founded in 1994, ANGLE is an international venture management company focusing on the commercialisation of technology and the development of technology-based industry. ANGLE creates, develops and advises technology businesses on its own behalf and for its clients.

ANGLE's specialist Management services business provides support on a fee-for-service basis to major clients around the world involved in incubation, IP commercialisation, SME innovation and growth and the operation of science & technology parks.

ANGLE also owns a portfolio of companies with high growth potential in the medical and technology sectors in both the UK and the US. These have been developed whilst subsidiaries of ANGLE using its proprietary Progeny® process. ANGLE seeks to retain a substantial shareholding in these companies with a view to ongoing returns from dividend, milestone, royalty and capital returns.

ANGLE's venture management and technology commercialisation skills are of increasing relevance as global economies focus on regeneration, innovation and value added components to their industries. ANGLE's technology skills in IT and software, medical and life sciences, clean tech and renewable energies are directly relevant to major growth markets of the future and are marketed as specialised Management services.

ANGLE is quoted on AIM (AGL.L); further information can be found on www.ANGLEplc.com 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
CNTUNRNRKORAUAA
Date   Source Headline
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery
5th Dec 20237:00 amRNSANGLE launches Portrait+ CTC kit at SABCS
9th Nov 20237:00 amRNSLaunch of PD-L1 test to support cancer studies
9th Nov 20237:00 amRNSTrading and business update
25th Oct 20237:00 amRNSSupporting characterisation of CTCs in HNSCC
3rd Oct 20237:00 amRNSParsortix outperforms standard for DTC harvest
29th Sep 20237:00 amRNSParsortix system showcased at ACTC conference
7th Sep 20237:00 amRNSInterim Results for the period ended 30 June 2023
4th Sep 20237:00 amRNSANGLE launch of Portrait Flex assay
15th Aug 20237:00 amRNSANGLE notice of interim results
28th Jun 20234:54 pmRNSResult of 2023 Annual General Meeting
27th Jun 202312:24 pmRNSStandard form for notification of major holdings
5th Jun 20237:00 amRNSANGLE announces senior management appointments
25th May 20237:00 amRNSPharma services contract with Artios Pharma
22nd May 20237:00 amRNSBoard change - appointment of new Chairman
21st Apr 202312:04 pmRNSANGLE presentation via Investor Meet Company
21st Apr 20237:00 amRNSResults for the year ended 31 December 2022
19th Apr 20237:00 amRNSANGLE announces partnership with BioView
17th Apr 20237:00 amRNSANGLE Parsortix poster presented at AACR 2023
13th Apr 20237:00 amRNSPharma Services Contract with Crescendo Biologics
3rd Apr 20237:00 amRNSNotice of Preliminary Results and Webcast
10th Mar 20237:00 amRNSIssue of LTIP Options and Share Options
9th Mar 20233:03 pmRNSHolding(s) in Company
9th Feb 20232:44 pmRNSDirector/PDMR shareholding
19th Jan 20237:00 amRNSAppointment of Non-Executive Director
11th Jan 20235:20 pmRNSHolding(s) in Company
10th Jan 20236:20 pmRNSHolding(s) in Company
6th Jan 202311:05 amRNSSecond Price Monitoring Extn
6th Jan 202311:00 amRNSPrice Monitoring Extension
5th Jan 20239:05 amRNSSecond Price Monitoring Extn
5th Jan 20239:00 amRNSPrice Monitoring Extension
5th Jan 20237:01 amRNSAppointment of Non-Executive Director
5th Jan 20237:00 amRNSBusiness Update
12th Dec 20227:00 amRNSTwo Parsortix posters presented at SABCS
2nd Dec 20225:30 pmRNSIssue of Equity
2nd Nov 20227:00 amRNSMultiple downstream analysis techniques for CTCs
1st Nov 20224:41 pmRNSSecond Price Monitoring Extn
1st Nov 20224:35 pmRNSPrice Monitoring Extension
24th Oct 20227:00 amRNSParsortix poster presented at ISLB meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.